Should enoxaparin (Lovenox) be held before an endoscopic retrograde cholangiopancreatography (ERCP), and what is the appropriate discontinuation interval based on therapeutic versus prophylactic dosing and renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Enoxaparin Before ERCP

Yes, enoxaparin must be held before ERCP with sphincterotomy, with the last dose administered 12-24 hours prior to the procedure. 1

Risk Classification of ERCP

ERCP with sphincterotomy is classified as a high-risk bleeding procedure by the British Society of Gastroenterology and European Society of Gastrointestinal Endoscopy. 1, 2 This classification mandates specific anticoagulation management protocols that differ substantially from low-risk diagnostic procedures.

  • ERCP with biliary or pancreatic stenting alone (without sphincterotomy) is considered low-risk and requires different management. 1
  • The addition of sphincterotomy, large balloon papillary dilation, or ampullectomy elevates the procedure to high-risk status. 1

Discontinuation Protocol for Enoxaparin

Standard Timing

Discontinue enoxaparin 12-24 hours before ERCP if sphincterotomy or other high-risk interventions are planned. 1 This timing allows adequate clearance of anticoagulant effect while minimizing thrombotic risk.

Bridging Considerations

The decision to hold enoxaparin depends on whether it is being used as:

  • Primary anticoagulation (therapeutic dosing): Hold 12-24 hours before procedure 1
  • Bridge therapy for warfarin: The same 12-24 hour hold applies, with transition to unfractionated heparin per institutional protocol if needed 1

For patients at high thrombotic risk (mechanical mitral valve, recent stent placement within specified timeframes, or atrial fibrillation with mitral stenosis), coordinate with cardiology before discontinuing enoxaparin, as these patients may require transition to unfractionated heparin that can be stopped closer to procedure time. 1, 2

Renal Function Adjustment

While the evidence specifically addresses CABG rather than ERCP, patients with impaired renal function (CrCl 30-50 mL/min) may require longer discontinuation periods due to prolonged enoxaparin clearance. 3 Consider extending the hold to 24 hours in patients with significant renal impairment to ensure adequate drug clearance.

Resumption After ERCP

Resume enoxaparin 24-72 hours after the procedure depending on bleeding risk and adequacy of hemostasis. 2 For high-risk procedures like ERCP with sphincterotomy, err toward the longer end of this interval (48-72 hours) to minimize post-procedural bleeding complications. 1

  • Verify adequate hemostasis before restarting anticoagulation 2
  • Coordinate resumption timing with the endoscopist who performed the procedure 1

Critical Pitfalls to Avoid

Never continue therapeutic-dose enoxaparin through ERCP with sphincterotomy, as this dramatically increases bleeding risk without providing meaningful additional thrombotic protection during the brief interruption period. 1, 4

Do not use bridging therapy with LMWH for patients at low thrombotic risk, as this increases bleeding complications without reducing thrombotic events. 1 Bridging is reserved only for patients at genuinely high thrombotic risk (mechanical mitral valve, recent drug-eluting stent <12 months, bare metal stent <1 month). 1

Avoid holding enoxaparin for longer than necessary (>24 hours before procedure), as each additional day off anticoagulation increases thrombotic risk, particularly in patients with active venous thromboembolism or high-risk atrial fibrillation. 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Direct Oral Anticoagulants Before Digestive Endoscopy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prevention and management of adverse events of endoscopic retrograde cholangiopancreatography.

Gastrointestinal endoscopy clinics of North America, 2013

Related Questions

How long should Lovenox (enoxaparin) be held prior to an esophagogastroduodenoscopy (EGD)?
How is the dose of Lovenox (enoxaparin) calculated?
Do I need to withhold aspirin (acetylsalicylic acid) and Clexane (enoxaparin) prior to a procedure?
What is the recommended anticoagulation regimen for patients with a portal vein graft, specifically using Clexane (enoxaparin) for heparin bridging?
Should thromboprophylactic enoxaparin be suspended on the day of surgery?
What are the introduction, clinical features, and management of folliculitis decalvans?
How should I evaluate and manage a patient suspected of desmoplakin (DSP)‑related arrhythmogenic cardiomyopathy, given a personal or family history of unexplained cardiomyopathy, ventricular arrhythmias, or sudden cardiac death?
Why give levothyroxine to a patient with painless (sub‑acute lymphocytic) thyroiditis who has entered the hypothyroid phase with elevated thyroid‑stimulating hormone or symptoms of hypothyroidism?
Will a non-diabetic person achieve modest weight loss by taking empagliflozin (SGLT‑2 inhibitor), and what are the associated risks?
What is the appropriate treatment for polyclonal gammopathy?
A 50‑year‑old woman with major depression and metastatic breast cancer presents with a two‑month history of polyuria and polydipsia; labs reveal hypernatremia, low urine osmolality, and otherwise normal renal function and vital signs. Which is the most likely diagnosis: diabetes insipidus, adipsic hypernatremia, or psychogenic polydipsia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.